A computer‐aided drug repurposing: the antibacterial agents targeting GroEL

This study validated our computational workflow for repurposing non-antibacterial drugs as antibacterial agents, demonstrating that cost-effective, computer-aided drug repurposing is a feasible strategy for identifying new therapeutic approaches to diseases, such as cancer, diabetes and COVID-19. Furthermore, the synergistic effect of daprodustat combined with an efflux pump inhibitor (e.g. PAβN) represents a promising therapeutic approach against both Gram-positive and Gram-negative bacterial pathogens.